Voice Articles
The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity
Cardiac toxicities are associated with many types of cancer therapies, with both length of and time since treatment increasing a patient’s risk for the adverse event. Anthracycline chemotherapies are among the oldest agents still used for a variety of cancer diagnoses, and as cancer survivorship continues to grow, more patients are presenting with late-onset cardiac complications.